Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology

被引:79
作者
Andrici, Juliana [1 ,2 ]
Sheen, Amy [1 ,2 ]
Sioson, Loretta [1 ,2 ]
Wardell, Kathryn [2 ]
Clarkson, Adele [1 ,3 ]
Watson, Nicole [1 ]
Ahadi, Mahsa S. [1 ,3 ]
Farzin, Mahtab [1 ,3 ]
Toon, Christopher W. [1 ,2 ,4 ]
Gill, Anthony J. [1 ,2 ,3 ,5 ]
机构
[1] Kolling Inst Med Res, Canc Diag & Pathol Res Grp, Sydney, NSW, Australia
[2] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia
[3] Royal N Shore Hosp, Dept Anat Pathol, Sydney, NSW 2065, Australia
[4] Histopath Pathol, Sydney, NSW, Australia
[5] Royal N Shore Hosp, Sydney Vital Translat Res Ctr, Sydney, NSW 2065, Australia
关键词
MALIGNANT MESOTHELIOMA; PREDISPOSITION SYNDROME; PATHOLOGICAL DIAGNOSIS; PLEURAL MESOTHELIOMA; CONSENSUS STATEMENT; PROGNOSTIC-FACTORS; P16; FISH; MUTATIONS; IMMUNOHISTOCHEMISTRY; GLUT-1;
D O I
10.1038/modpathol.2015.87
中图分类号
R36 [病理学];
学科分类号
100103 [病原生物学];
摘要
Although most mesotheliomas present with pleural effusions, it is controversial whether mesothelioma can be diagnosed with confidence in effusion cytology. Therefore, an ancillary marker of malignant mesothelial cells applicable in effusions would be clinically valuable. BRCA-1-associated protein (BAP1) is a tumor suppressor gene, which shows biallelic inactivation in approximately half of all mesotheliomas. We investigated whether loss of BAP1 expression by immunohistochemistry can be used to support a diagnosis of mesothelioma in effusion cytology. Immunohistochemistry for BAP1 was performed on cell blocks and interpreted blinded. 43 of 75 (57%) effusions associated with confirmed mesothelioma showed negative staining with positive internal controls. Of 57 effusions considered to have atypical mesothelial cells in the absence of a definitive diagnosis of mesothelioma, 8 cases demonstrated negative staining for BAP1. On follow-up six of these patients received a definitive diagnosis of mesothelioma in the subsequent 14 months (two were lost to follow-up immediately, and mesothelioma could not be excluded). Only 5 of 100 consecutive benign effusions were interpreted as BAP1 negative. One of these patients died soon after and mesothelioma could not be excluded. On unblinded review the four other patients with apparently negative BAP1 staining but no malignancy lacked convincing positive staining in non-neoplastic cells suggesting that BAP1 immunohistochemistry may have initially been misinterpreted. 47 effusions with adenocarcinoma were BAP1 positive. We conclude that loss of BAP1 expression, while not definitive, can be used to support the diagnosis of mesothelioma in effusion cytology. We caution that interpretation of BAP1 immunohistochemistry on cell block may be difficult and that convincing positive staining in non-neoplastic cells is required before atypical cells are considered negative. We also note that BAP1 loss is not a sensitive test as it occurs in only half of all mesotheliomas and cannot be used to exclude the diagnosis.
引用
收藏
页码:1360 / 1368
页数:9
相关论文
共 32 条
[1]
Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers [J].
Abdel-Rahman, Mohamed H. ;
Pilarski, Robert ;
Cebulla, Colleen M. ;
Massengill, James B. ;
Christopher, Benjamin N. ;
Boru, Getachew ;
Hovland, Peter ;
Davidorf, Frederick H. .
JOURNAL OF MEDICAL GENETICS, 2011, 48 (12) :856-859
[2]
The Importance of Multidisciplinary Approach in Early Detection of BAP1 Tumor Predisposition Syndrome: Clinical Management and Risk Assessment [J].
Battaglia, Angelo .
CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2014, 8 :37-47
[3]
Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesis [J].
Baud, Mariette ;
Strano, Salvatore ;
Dechartres, Agnes ;
Jouni, Rami ;
Triponez, Frederic ;
Chouaid, Christos ;
Forgez, Patricia ;
Damotte, Diane ;
Roche, Nicolas ;
Regnard, Jean-Francois ;
Alifano, Marco .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2013, 145 (05) :1305-1311
[4]
Inference on Germline BAP1 Mutations and Asbestos Exposure from the Analysis of Familial and Sporadic Mesothelioma in a High-Risk Area [J].
Betti, Marta ;
Casalone, Elisabetta ;
Ferrante, Daniela ;
Romanelli, Antonio ;
Grosso, Federica ;
Guarrera, Simonetta ;
Righi, Luisella ;
Vatrano, Simona ;
Pelosi, Giuseppe ;
Libener, Roberta ;
Mirabelli, Dario ;
Boldorini, Renzo ;
Casadio, Caterina ;
Papotti, Mauro ;
Matullo, Giuseppe ;
Magnani, Corrado ;
Dianzani, Irma .
GENES CHROMOSOMES & CANCER, 2015, 54 (01) :51-62
[5]
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma [J].
Bott, Matthew ;
Brevet, Marie ;
Taylor, Barry S. ;
Shimizu, Shigeki ;
Ito, Tatsuo ;
Wang, Lu ;
Creaney, Jenette ;
Lake, Richard A. ;
Zakowski, Maureen F. ;
Reva, Boris ;
Sander, Chris ;
Delsite, Robert ;
Powell, Simon ;
Zhou, Qin ;
Shen, Ronglai ;
Olshen, Adam ;
Rusch, Valerie ;
Ladanyi, Marc .
NATURE GENETICS, 2011, 43 (07) :668-U81
[6]
A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes [J].
Carbone, Michele ;
Emri, Salih ;
Dogan, A. Umran ;
Steele, Ian ;
Tuncer, Murat ;
Pass, Harvey I. ;
Baris, Y. Izzettin .
NATURE REVIEWS CANCER, 2007, 7 (02) :147-154
[7]
Malignant Mesothelioma: Facts, Myths, and Hypotheses [J].
Carbone, Michele ;
Ly, Bevan H. ;
Dodson, Ronald F. ;
Pagano, Ian ;
Morris, Paul T. ;
Dogan, Umran A. ;
Gazdar, Adi F. ;
Pass, Harvey I. ;
Yang, Haining .
JOURNAL OF CELLULAR PHYSIOLOGY, 2012, 227 (01) :44-58
[8]
Germline BAP1 mutations predispose also to multiple basal cell carcinomas [J].
de la Fouchardiere, A. ;
Cabaret, O. ;
Savin, L. ;
Combemale, P. ;
Schvartz, H. ;
Penet, C. ;
Bonadona, V. ;
Soufir, N. ;
Bressac-de Paillerets, B. .
CLINICAL GENETICS, 2015, 88 (03) :273-277
[9]
Loss of expression of BAP1 predicts longer survival in mesothelioma [J].
Farzin, Mahtab ;
Toon, Christopher W. ;
Clarkson, Adele ;
Sioson, Loretta ;
Watson, Nicole ;
Andrici, Juliana ;
Gill, Anthony J. .
PATHOLOGY, 2015, 47 (04) :302-307
[10]
Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers [J].
Henderson, Douglas W. ;
Reid, Glen ;
Kao, Steven C. ;
van Zandwijk, Nico ;
Klebe, Sonja .
JOURNAL OF CLINICAL PATHOLOGY, 2013, 66 (10) :847-853